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RESUMEN
Antecedentes: durante varios años, se han realizado muchos intentos para mejorar la estabilidad lipo-
somal. En 1986, Payne et al, introdujeron el concepto de pro-liposoma para la preparación de liposoma 
con el fin de evitar la inestabilidad fisicoquímica encontrada en algunas suspensiones de liposoma tales 
como agregación, fusión, hidrólisis, y/o oxidación.
Objetivo: el objetivo de esta revisión es centrarse en diferentes aspectos relacionados con los Proliposo-
mas, su método de preparación, técnicas de caracterización, asi como señalar su alcance en los sistemas 
de administración de fármacos.
Métodos: los Proliposomas son una nueva forma de sistemas de administración de fármacos. Son pro-
ductos granulares secos y de flujo libre compuestos por fármacos y fosfolípidos que, al añaderse el agua, 
se dispersan para formar una suspensión liposomal multilamelar.
Resultados y discusión: estos Proliposomas son casi tan buenos o quizás mejores que los liposomas con-
vencionales. En la presente revisión se explica brevemente el concepto de Proliposomas con un enfoque 
en sus componentes, preparación, caracterizaciones y su campo de aplicación.
Conclusión: una extensa encuesta de literaturas y datos recogidos sugiere que los pro-liposomas son 
portadores de fármacos prometedores para el futuro.
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ABSTRACT
Background: For several years, many attempts have been made for the improvement of liposomal sta-
bility. In 1986, Payne et al, introduced the concept of Pro-liposome for liposome preparation in order 
to avoid physicochemical instability encountered in some liposome suspensions such as aggregation, 
fusion, hydrolysis, and/or oxidation.
Objective: The objective of this review is to focus on different aspects related to Proliposomes, their 
method of preparation, characterization techniques and pointing out its scope in drug delivery systems.
Methods: Proliposomes are a new form of drug delivery systems. They are dry, free-flowing granular 
products composed of drug and phospholipid which, upon addition of water, disperse to form a mul-
ti-lamellar liposomal suspension.
Results and Discussion: These Proliposomes are nearly as good as or perhaps better than conventional 
liposomes. In the present review attempt has been made to briefly explain the concept of Proliposomes 
with a focus on its components, preparation, characterizations and their field of application.
Conclusion: Extensive survey of literatures and collected data suggests that Pro-liposomes are promis-
ing drug carriers for the future.
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INTRODUCTION
Liposomes are sphere-shaped vesicles consisting of one 
or more phospholipid bilayers. Liposomes can trap both 
hydrophobic and hydrophilic compounds, avoid decom-
position of the entrapped combinations, and release the 
entrapped at designated targets. The liposome can be used 
as a vehicle for administration of nutrients and pharma-
ceutical drugs. Additionally, food and farming industries 
have extensively studied the use of liposome encapsulation 
to grow delivery systems that can entrap unstable com-
pounds (for example, antimicrobials, antioxidants, flavours 
and bioactive elements) and shield their functionality. Due 
to their size and hydrophobic and hydrophilic character 
(besides biocompatibility), liposomes are promising sys-
tems for drug delivery1,2. Inspite of its broad applications 
and advantages, liposomes have a problem of degradation 
by hydrolysis or oxidation as well as sedimentation, aggre-
gation, or fusion with other liposomes in dispersed system 
during non-lyophilized storage. Other drawbacks asso-
ciated with the clinical applications of liposomes include 
difficulties in large-scale production to obtain a product 
with adequate physical and chemical stability, low solubil-
ity, short half-life and sometimes leakage of encapsulated 
drug/molecules3,4. Various approaches have been suggest-
ed to increase the stability of liposomes, including using 
appropriate lipid compositions, polymer coating, addition 
of stabilizing lipids to liposomal structures, preparation of 
double liposomes and proliposomes and some other inno-
vative methods like lyophilization of liposomal solution to 
stabilize, reconstitute right before use4,5. Among all these 
approaches Proliposome approach is most promising.
The review gives an insight on Proliposomes based ap-
proach for the development of a stable liposome and ex-
plore its various aspects including its formulation com-
ponents, preparation, characterization and its potential in 
drug delivery applications. An extensive literature search 
was conducted via search engine Google Scholar and data-
bases: PubMed, Science Direct and Springer to summarize 
the data comprising information on formulation, develop-
ment, characterization and applications of proliposomes 
from 80’s till date.
Proliposomes are a new type of carrier mediated drug de-
livery system having many benefits over conventional li-
posomes. The stability of proliposomes is far superior to 
liposomes making them more suitable for the delivery of 
drugs. They are a dry, free-flowing, granular material that 
immediately forms a liposomal dispersion on contact with 
water or a biological fluid within the body 5,6,7. Compara-
tive features of Liposomes and Proliposomes is shown in 
Figure 1.
Figure 1. Comparisons between Liposomes and Pro- liposomes14
The proliposome approach was developed as a simple, re-
producible, and reliable manufacturing technique for large-
scale production of liposome dispersions. The technology 
is based upon the intrinsic property of hydrated membrane 
lipids to form vesicles on contact with water. It involves 
layering of the phospholipids onto a finely divided particu-
late support which results in the formation of dry powders. 
When the dry powders are hydrated with an aqueous solu-
tion followed by gentle mixing, phospholipids on the solid 
support rapidly disperses to give a liposomal suspension 
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in an aqueous solution5,6,7. Liposomes can either be formed 
in vivo under the influence of physiological fluids or can 
be formed in vitro prior to administration using a suitable 
hydrating fluid. The liposomes formed on reconstitution 
are similar to conventional liposomes and more uniform in 
size7,8. The mechanism of formation of liposome from proli-
posome is demonstrated in Figure 2.
Figure 2. Mechanism of formation of Liposomes from Proliposome
Proliposomes have been employed as a basis for a number 
of site-specific drug delivery approaches. Proliposomal for-
mulations suggest increases solubility and bioavailability 
of some poorly soluble drugs. Being available in dry pow-
der form, they have an additional convenience in trans-
portation, distribution, storage, processing, packaging, 
providing optimal flexibility, unit dosing as capsule and 
stable during sterilization. All these advantages make them 
a promising candidate for industrial production. These ver-
satile delivery systems have potential to be used as a carrier 
for wide range of active compounds7,9.
FORMULATION COMPONENTS FOR PROLIPOSOMES
Formulation of proliposomes involves several components:
Figure 3. Formulation components for Proliposomes
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Phospholipids
A wide range of lipids are available for the preparation 
of proliposomes. Phosphatidylcholines (PC) are the most 
frequently used phospholipids. PCs also known as lecithin 
can be obtained from natural and synthetic sources. They 
differ from other amphipathic molecules in the formation 
of bilayer sheets compared with micellar structures. Nat-
ural PCs are commonly derived from egg yolk, soy bean 
and very rarely from bovine heart and spinal cord. They 
are typically used as the principal component in prolipos-
omes, due to their relatively low cost, lack of net charge 
and chemical inertness. Additionally, to PC, neutral lipid 
bilayers are composed of sphingomyelin (SM). Polar head 
groups such as phosphatidylglycerol (PG), phosphatidy-
lethanolamine (PE), phosphatidic acid (PA), phosphatidyl-
serine (PS), and Phosphatidylcholines (PC) combined with 
various fatty acid chains such as oleic, lauryl, myristic, 
palmitic and stearic acid offering variety of phospholipid 
structures. Inspite of availability of wide variety of phos-
pholipids, preparation of proliposomes is often limited to 
the family of PCs and PGs, mainly because of toxicological 
considerations, purity, stability and cost 1,3,4,5.
Steroids
Cholesterol and its derivatives are quite often included 
as components of liposomal membrane. Their inclusion 
in liposomal membranes has three recognized effects. In-
creasing the fluidity or micro viscosity, reducing the per-
meability of the membrane to water soluble molecules and 
stabilizing the membrane in the presence of biological flu-
ids such as plasma. Its incorporation into phospholipid bi-
layers causes major changes in their properties. Cholesterol 
does not by itself form bilayers, but it can be incorporated 
into phospholipid membranes in high concentrations. It 
improves the retention of hydrophilic drugs by increasing 
the rigidity of the bilayers and reducing the permeability, 
however for hydrophobic drugs it improves encapsulation, 
only if the drug input is less than the encapsulation capaci-
ty of the liposome 10,11, 12.
Water soluble carriers
The carriers chosen should have high surface area and po-
rosity so that the amount of carrier required can be easily 
adjusted to support the lipids. It also allows high surfactant 
to carrier mass ratio within the preparation of proliposomes. 
Since they are water soluble they allow rapid conversion of 
liposomal dispersion on hydration and by controlling the 
size of porous powder, relatively narrow range of reconsti-
tuted liposomes can be obtained. Some of the carriers used 
are- Maltodextrin, Mannitol, Sorbitol, Microcrystalline Cel-
lulose, Magnesium Aluminium Silicates, etc1,4.
Solvents
They are used for providing the softness to vesicle mem-
brane. Most commonly used volatile organic solvent or 
solvent mixtures are ethanol, methanol, ether and chloro-
form13.
METHODS FOR PREPARATION OF PROLIPOSOMES
Various methods are available for the preparation of proli-
posomes. Careful selection of suitable method for a given 
formulation is essential since various factors such as vesicle 
size, size distribution, encapsulation capability and reten-
tion of contents are affected by the method of preparation. 
Selection of a given method is based on physicochemical 
characteristics of the drug, desired type of phospholipid(s), 
particle size range and ease of preparation. An ideal meth-
od of preparation should involve minimal use of organic 
solvent, avoid long exposure to mechanical stress, employ 
low temperature and pressure, be reproducible and eco-
nomical, yield a high drug/lipid ratio and be adaptable for 
large scale production 1,13,14.
a. Film deposition on carrier method
In this method, firstly lipid is mixed with a solid substrate 
(water soluble carrier) which forms lipid coated solid parti-
cles. Upon hydration, solid substrate is dissolved and lipids 
arrange to form liposomes. Figure 4 A, shows an apparatus 
for preparing proliposomes by film deposition on carrier 
method in which an evaporative solution consisting of a 
solution of drug and phospholipids is added drop by drop 
by injection through a feed tube onto a core of carrier sub-
stance which is carried in a vessel of a rotary flash evapo-
rator under vacuum. At any stated moment, the matrix’s 
over wetting is circumvented and following aliquot of or-
ganic mixture is fed slowly when a free-flowing powder 
matrix is procured. Selected carriers should exhibit great 
surface area and permeability to regulate the quantity of 
carrier which is needed to assist the lipids. This also allows 
great surfactant to carrier mass proportion for the pro-li-
posomes production. As they are water soluble, they enable 
fast production of liposomal dispersion on hydration and 
by controlling the size of pervious powder, comparatively 
limited variety of reconstituted liposomes can be obtained. 
The most commonly used carriers are maltodextrin, sorbi-
tol, microcrystalline cellulose, magnesium aluminium sili-
cates, mannitol, etc14.
b. Spray drying method
This method is mainly used when particles of uniform size 
and shape are required and can be easily scaled up in a cost 
effective way that is suitable for large scale production of 
proliposomes. The unique feature of spray drying process 
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lies in its ability to involve both particle formation and dry-
ing in a continuous single step, allowing better control of 
particle. Spray drying is not only limited to aqueous solu-
tions, but can also be used for non-aqueous systems to pre-
pare particles. Figure 4 B shows the various stages involved 
in spray drying process. Firstly, liquid dispersions carrying 
pure lipid or lipids and carriers in organic mixture is pre-
pared and then the dispersion is poured into a dry cell. Dis-
persions are atomized in the drying cell utilizing a spray 
nozzle and desiccated in a simultaneous air flow which is 
then collected in a tank 15.
c. Fluidized bed method
Fluidized bed method is used for the large scale produc-
tion of proliposomes. Apparatus for preparing prolipos-
omes by Fluidized bed method is shown in Figure 4 C. 
This method is based on the principle of particle coating 
technology. Here, carrier material can vary from crystalline 
powder to non pareil beads. When non pareil beads are 
used as carrier material, first pareil beads are coated with 
seal coating to get smooth surface which can help further 
in coating of phospholipids and also ensure thin uniform 
coating formation of phospholipids around the core and 
small sized liposomes upon hydration. Carrier material 
sprayed with the solution of organic solvent and solution 
of drugs through nozzle. At the same time, organic solvent 
is removed by applying vacuum to the fluid bed. The trace 
amount of residual solvent is removed from the finished 
lipid-coated powder/beads when dried under vacuum 
overnight 9,16.
d. Supercritical anti-solvent method
Supercritical anti-solvent method utilizes Supercritical Car-
bon dioxide (SCCO2) in the preparation of proliposomes. 
SCCO2 is a fluid state of carbon dioxide where it is held 
at or above its critical temperature and pressure. The ap-
paratus used in the preparation of proliposomes include 
following parts (See Figure 4 D): CO2 syringe pump; circu-
lar and cooling lines for maintaining the CO2 pump head 
and CO2, which flowed out of a storage tank (-7°C); and a 
reaction vessel containing a magnetic stirrer, pressure in-
dicator, and temperature indicator. Firstly, a clear and ho-
mogenous solution of phospholipids, cholesterol and drug 
is prepared. The drug–lipid solution and carrier material 
is then sealed in the reaction vessel. The supercritical CO2 
pumped to the vessel by a syringe pump. After approxi-
mately 30 minutes of stirring at equilibrium, additional su-
percritical CO2 continued to flow into the vessel for about 
30 minutes to wash out any remaining solvents. The vessel 
is then slowly depressurized to atmospheric pressure, and 
drug-phospholipid mixture coated the surface of carrier 
particles, forming a thin film. SCF mediated pro- liposomes 
is then collected and stored at 4°C 16,17,18.
Figure 4. Apparatus for preparation of Proliposomes
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CHARACTERIZATION OF PROLIPOSOMES
Proliposomes are characterized for morphology, angle of 
repose, rate of hydration, penetration and permeation stud-
ies.
Particle size
Particle size of proliposome is a very important characteris-
tic. Size distribution and surface morphology (smoothness, 
roundness and aggregates formation) of particles can be 
studied by scanning electron microscopy (SEM). The depo-
sition of phospholipid on the carrier material is confirmed 
by illegibility of the image of the carrier material in the for-
mulation of proliposomes 19.
Hydration Study and Vesicle formation
It is important to determine the formation of liposomal ves-
icle following hydration of the proliposomal formulation in 
vitro. The vesicle formation by the particular procedure can 
be confirmed by optical microscopy. The liposome suspen-
sion has to be placed over a glass slide and dried at room 
temperature, the dry thin film of liposome suspension 
formed has to be observed for the formation of vesicles 6, 14.
Measurement of zeta potential
Another characteristic of proliposomes is zeta potential that 
is of extreme interest. It is a measure of the particle charge, 
the larger the zeta potential absolute value the larger the 
amounts of surface charge. Logically, the zeta potential is 
an index for particle stability. A physically stable proliposo-
mal formulation solely stabilized by electrostatic repulsion 
will have a ±30mV of minimum zeta potential and this sta-
bility helps in preventing aggregation 20.
Separation of unentrapped drug
Free or unentrapped drug can be separated by centrifuga-
tion of liposomal suspension, the pellets and supernatant 
are separated. The obtained pellets are washed and then 
resuspended to obtain a liposomal suspension free from 
unentrapped drug.
Gel filtration is another method used for separation of un-
entrapped drug from liposomal dispersion using a Sepha-
dex-G-50 column, eluted with suitable mobile phase and 
analysed with suitable analytical techniques 2, 21.
Differential Scanning Calorimetry and Powder X-ray 
Diffractometry
Differential scanning calorimetry (DSC) and powder X-ray 
diffractometry (PXRD) can be used to determine the solid 
state properties of drug after formulating in to prolipos-
omes i.e., changes in its form from crystalline to amor-
phous. This is especially important when the drug’s solu-
bility was improved using proliposomal formulation 22.
Flow Properties
Flow properties mainly explain content uniformity and 
handling processing operations and also ease filling. Since 
it is a solid powder based formulation, it is important to 
analyse the flow properties in order to translate them into a 
convenient dosage forms such as tablets or capsules. Flow 
properties can be assessed by measuring the parameters 
such as bulk density, tapped density, angle of repose, Carr’s 
compressibility index and Hausner’s ratio 23.
Determination of entrapment (entrapped) efficiency
Entrapment efficiency is carried by hydrating the prolipos-
omes to form liposome dispersion followed by separation 
of unentrapped drug and determining the amount of drug 
entrapped. Untrapped or free drug can be separated by us-
ing any one of the method described above 24,25.
In vitro drug release from proliposomes
In vitro drug release studies for proliposomes can be done 
by various techniques such as USP dissolution apparatus 
Type I, Franz diffusion cell, dialysis tubing, reverse dialysis, 
cellophane dialyzing membrane, keshary-chien diffusion 
cell and spectrapormolecular porous membrane tubing.
In vitro skin permeation studies can be carried out using 
flank skin, dorsal skin of albino rabbit, female albino rat 
(Sprague-Dawley strain), Wistar rat skin (7–9 weeks old) 
2,7, 21,23,26,27.
Stability studies
The stability studies can be performed by storing the sam-
ples at different temperatures like freezing temperature (2-
8ºC), room temperature (25±0.5ºC) and higher temperature 
(45±0.5ºC) for a period of 1–3 months. Periodically, drug 
content and difference in the average vesicle diameter can 
be observed. According to ICH guidelines, dry prolipos-
ome powder meant for re-formulation should be consid-
ered for accelerated stability at relative humidity 75%/40ºC 
as per international climatic conditions and zones. Long-
term stability studies have to be conducted based on the 
climatic zones of the countries. Temperature and relative 
humidity to be maintained for zones I & II and III & IV are 
25ºC/60% RH and 30ºC/65% RH, respectively. The product 
should be evaluated for appearance, surface characteristics, 
drug content, color change, pH, particulate matter, assay, 
preservative content, pyrogenicity and sterility 2,21,28.
237Ars Pharm. 2019; 60(4): 231-240
Proliposomes: An Approach for the Development of Stable Liposome
APPLICATION OF PROLIPOSOMES IN DRUG DE-
LIVERY
Proliposomes have been studied for various routes of ad-
ministration including oral, transdermal, mucosal, nasal, 
ocular, pulmonary and parenteral. Proliposomes derived 
liposomes showing advantages as drug carriers, compris-
ing lower cost and toxicity, easy storage and handling and 
increased stability. Various applications of proliposomes 
are shown in Table 1.
Proliposome in Oral delivery
Oral drug delivery continues to be the preferred route of 
administration, but liposomes have limited success in de-
livering drugs through oral route due to a lack of stability, 
erratic and unpredictable absorption profiles. Being avail-
able as a free flowing powder, Proliposomes represent the 
first example of delivering liposomes into solid dosage form 
such as tablets or capsules. Further, liposomes are formed 
on contact with biological fluids at the site of absorption en-
suring the retention of liposome integrity29. Domperidone 
is a specific 5HT3 receptor antagonist used in the treatment 
of nausea and vomiting. It has low aqueous solubility and 
moreover after oral administration it undergoes extensive 
gastric and hepatic first pass metabolism. Dhurke et al, 
made an attempt to develop proliposomes of domperidone 
with an aim to improve bioavailability by increasing intes-
tinal permeability which would transport drug through 
the lymphatic transport system and bypassing first pass 
metabolism30. Chuandi et al, investigated the possibility of 
liquid proliposomes being carriers for oral delivery. They 
prepared liquid proliposomes based on soft capsules of Ni-
modipine and reported that proliposomes show improved 
oral delivery of Nimodipine31. Proliposomes could also be 
a useful vehicle for oral delivery of dehydrosilymarin, a 
poorly soluble drug in water. Chu et al, prepared prolipos-
ome of dehydrosilymarin with a polyphase dispersed sys-
tem consisting of soybean phospholipids, cholesterol, iso-
propyl myristate and sodium cholate. Dehydrosilymarin 
proliposomes prepared by a film dispersion-freeze drying 
showed improved oral bioavailability of dehydrosilymarin 
29.
Proliposome in Transdermal delivery
Phospholipids, being the main component of liposomal 
system, will simply get integrated with the skin lipids and 
maintain the desired hydration conditions to enhance drug 
permeation. When proliposomes are applied to the mucosal 
membrane, they are expected to form liposomes on contact 
with mucosal fluids whereby the resulting liposomes act 
as sustained release dosage form for loaded drugs. Lipos-
omes formed on hydration can modulate diffusion across 
the skin32,33,34. Several investigations have been made to ex-
amine the feasibility of proliposomes as a sustained trans-
dermal dosage form. Hwang et al prepared proliposomes 
containing varying amounts of Nicotine using sorbitol and 
lecithin35. In the investigation made by Shruthi et it was 
found that proliposomal gel of transdermal Metformin 
hydrochloride allows delivery of drug through the skin 
with significant reduction of glucose level14. Kumara et al 
prepared proliposomal gel system of Repaglinide to deliv-
er the drug over an extended period for the treatment of 
type - 2 diabetes mellitus. Results obtained confirmed pro-
liposomes was a better choice for controlled release of drug 
through topical drug delivery36. Diwan et al, prepared pro-
liposomal gel of Prednisolone, a steroidal anti-inflammato-
ry agent intended for topical application and reported that 
Prednisolone proliposomal gel showed sustain release with 
enhanced anti-inflammatory activity indicating its poten-
tial role in the treatment of rheumatoid arthritis37. Kuraku-
la et al, prepared proliposomal gel bearing a non-steroidal 
anti-inflammatory agent Piroxicam for topical application. 
Piroxicam proliposomal gel showed sustain release with 
enhanced anti-inflammatory activity 38.
Proliposome in Mucosal delivery
Proliposomes form vesicular structures (liposomes) in vivo, 
triggered by the aqueous environment found on the mu-
cosal surfaces. Phospholipids present in them have a natu-
ral affinity for biological membranes. The presence of drug 
as molecular dispersion in the bilayers offers improved 
drug activity. Further, the difficulties associated with lipo-
somal preparations such as stability and loading are cir-
cumvented because the proliposomes convert to vesicular 
structures in vivo, i.e., on the mucosa 39, 40. Ning et al, devel-
oped Clotrimazole(CT)-containing vaginal proliposomes 
for prolonged drug release that increases the amount of 
drug retention into the mucosa which resulted in increased 
antifungal efficacy 39.
Proliposome in Ophthalmic delivery
Ocular drug delivery is challenging in terms of achieving 
optimum drug concentration due to unique protective 
mechanisms of the eye. Development of a drug delivery 
system for attaining therapeutic concentration at the tar-
get site requires a comprehensive understanding of static 
and dynamic barriers of the eye 41. Liposomes have been 
investigated for ophthalmic drug delivery as they offer ad-
vantages as a carrier system. They are biodegradable and 
nanocarriers. They can enhance the permeation of poorly 
absorbed drug molecules by binding to the corneal surface 
and improving residence times. Karn et al, developed a dry 
proliposome containing Cyclosporin A for use in the treat-
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ment of several autoimmune, parasitic diseases and vari-
ous inflammatory ocular surface disorder 42.
Proliposome in Pulmonary delivery
Proliposomes have been shown to be very promising in 
the delivery of various types of pulmonary drugs 43. Ro-
janarat et al, designed Levofloxacin (LEV)- proliposomes 
in a dry powder aerosol form for pulmonary delivery. 
LEV-proliposomes were less toxic to the respiratory-asso-
ciated cells than LEV, and did not activate AMs (Alveolar 
macrophages) to produce inflammatory mediators. The 
efficacy of LEV-proliposomes against M. bovis was signif-
icantly higher than that of free LEV 44. Patil et al, prepared 
Rifapentine loaded proliposomes for the treatment of tu-
berculosis by spray drying method and independent var-
iables were optimized using a factorial design approach45. 
Kajornwongwattana et al, prepared proliposome powders 
containing isoniazid (INH) in a dry powder aerosol form 
and studied for its toxicity to respiratory-associated cell 
lines and its potential to provoke immunological responses 
from alveolar macrophages (AM). Free INH and INH-pro-
liposome bioactivities were tested in vitro and in alveolar 
macrophages infected with Mycobacterium bovis (M. bovis). 
INH-proliposome exhibited better antimycobacterial activ-
ity against M. bovis-infected AM. Results obtained indicates 
INH-proliposomes are potential candidates for an alterna-
tive tuberculosis treatment 46. Pulmonary liposomal deliv-
ery system of budesonide was prepared and evaluated for 
sustained release 47. Liposomal formulation of salbutamol 
in dry powder form was also developed as sustained re-
lease systems for the pulmonary delivery48.
Proliposome in Nasal delivery
Nasal drug delivery has received a significant attention in 
recent years as a convenient and reliable route, not only 
for local but also for the systemic administration of drugs. 
Proliposomes have also shown their potential in nasal drug 
delivery. They provide combined advantage of a fast onset 
(surface drug) and prolonged drug action (encapsulated 
drug) 49, 50. Jung et al, performed to achieve prolonged de-
livery of nicotine to the systemic circulation. Proliposomes 
containing nicotine base (NB-proliposomes) or nicotine hy-
drogen tartarate salt (NS-proliposomes) and a mixture of 
powdered nicotine hydrogen tartrate salt and sorbitol (1:9 
mixtures, MP) were administered intranasally to rats at a 
nicotine dose of 1 mg/kg and reported prolonged delivery 
of nicotine to systemic circulation51. In another interesting 
study free flowing proliposomes containing propranolol 
hydrochloride (PH) were evaluated by Jung et al, for their 
potential as a nasal drug delivery system to sustain the 
plasma concentration of the drug 52.
Table 1. Some of the research work carried out on proliposome as drug carriers
S. No. Route Drug Application References
1 Oral Domperidone Proliposomes 30
2 Oral Nimodipine Proliposome based soft capsule 31
3 Oral Silymarin Proliposome 29
4 Transdermal Nicotine Proliposomal gel 35
5 Transdermal Metformin hydrochloride Proliposomal gel 14
6 Transdermal Repaglinide Proliposomal gel 36
7 Transdermal Prednisolone Proliposomal gel 37
8 Transdermal Piroxicam Proliposomal gel 38
9 Mucosal Clotrimazole Vaginal proliposomes 39
10 Ophthalmic Cyclosporine Dry proliposomes 42
11 Pulmonary Levofloxacin proliposomes in a dry powder aerosol 44
12 Pulmonary Isoniazid Proliposome powder 46
13 Nasal Nicotine Proliposomes 51
14 Nasal Propanolol HCl Proliposomes 52
15 IV Ibuprofen Proliposomes 53
16 IV Amphotericin B Proliposomes 6
17 IV Methotrexate Proliposomes 54
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CONCLUSIONS AND FUTURE PERSPECTIVES
Pro-liposomes are promising drug carriers for the future. 
They have provided a major breakthrough in solving the 
stability, bioavailability and solubility of poorly soluble 
drugs issues associated with liposomes and they offer a 
non-invasive delivery of drug into or across the skin. They 
are better alternative to the liposomal vesicular system 
due to their greater physical, chemical stability and poten-
tially scalable for commercial viability. Since they are dry 
powder form they are suitable for preparing unit dosages 
forms such as tablets, capsules and beads etc. Owing to all 
these advantages pro-liposomes has been used for broad 
range of pharmaceutical application. Proliposomes are ad-
ministered orally, parenterally, topically as well as used in 
cosmetic and hair technologies, sustained release formula-
tions, diagnostic purpose and as good carriers in gene de-
livery. Proliposomes are becoming a useful drug carrier for 
different delivery systems. Still there is a need for discov-
ering the new delivery systems using proliposomes in the 
field of nutraceuticals, herbal actives and other synthetic 
formulations. Hence, a wider research should be done to 
develop scale-up batches for drug and natural preparations
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